Logo Image

Giuseppe Curigliano

Articles by Giuseppe Curigliano

98 A Phase 1/2 Trial of LY4064809, A Pan-Mutant-Selective PI3Kα Inhibitor in HR+/HER2− Advanced Breast Cancer, Updated Results From PIKALO-1

ByKomal L. Jhaveri,Dejan Juric,Antonio Giordano,Antoine Italiano,Gennaro Daniele,Jordi Rodón,Amita Patnaik, MD,Jorge Bartolomé,Anthony D. Elias, MD,Pamela N. Munster, MD,Patricia Lorusso, DO,Aixa Soyano,Maria de Miguel,Joyce O’Shaughnessy, MD,Robert Wesolowski,Giuseppe Curigliano,Tatiana Hernández,Aurélie Lombard,Shawn T. Estrem,Lin Du,Xiaofan Xu,Alberto J. Montero, MD, MBA, CPHQ

99 Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial

ByKomal L. Jhaveri,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Phillippe Aftimos,Cristina Saura,Joyce O’Shaughnessy, MD,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,Junichiro Watanabe,Elgene Lim, MBBS, FRACP, PhD,Juan Huang,Qingyuan Zhang,Antonio Llombart-Cussac,Chiun-Sheng Huang,Bhardwaj Desai,Xuejing Aimee Wang,Shanshan Cao,Francois Clement Bidard

101 Patient-Reported Outcomes (PROs) in Patients With ER+, HER2- Advanced Breast Cancer (ABC) Treated with Imlunestrant, Investigator’s Choice Standard Endocrine Therapy, or Imlunestrant+Abemaciclib: Results From the Phase III EMBER-3 Trial

ByGiuseppe Curigliano,Joyce O'Shaughnessy, MD,François-Clément Bidard,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Lisa A. Carey, MD,Meena Okera,Everton Melo,Flora Zagouri,Manuel Ernesto Magallanes Maciel,Nuri Karadurmus,Shakeela Bahadur,Rebecca M Speck,Xuejing Aimee Wang,Suzanne Young,Komal L. Jhaveri,Nadia Harbeck, MD, PhD

102 Imlunestrant (imlu) With or Without Abemaciclib (abema) in Advanced Breast Cancer (ABC): Safety Analyses From the Phase III EMBER-3 Trial

ByJoyce O’Shaughnessy, MD,Francois Clement Bidard,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Philippe Aftimos,Cristina Saura,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,J A Garcia-Saenz,Maria Fernandez Abad,Larissa de Paula,Yeon Hee Park,Ozgur Ozyilkan,Maria Munoz,Sabrina Formentini,Emily Barrett,Shanshan Cao,Aarti Chawla,Komal L. Jhaveri

TIP103 Randomized Phase 3 Clinical Trial Evaluating Atirmociclib Plus Letrozole Versus a CDK4/6 Inhibitor Plus Letrozole as First-Line Treatment for Patients With HR+/HER2− Advanced/Metastatic Breast Cancer

ByFrancois Clement Bidard,Michail Ignatiadis,Giuseppe Curigliano,Binghe Xu,Theresa Link,Yoichi Naito,Huiping Li,Madoka Iwase,Mark A. Taylor,Carlos H Barrios,Tomofumi Osako,Kevin Kalinsky, MD, MS,Antonio Giordano,Shom Goel, MD,Libero Santarpia,Jason Quan Gong,Kathrine C. Fernandez,Zhe Zhang,Hope S. Rugo, MD

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)

ByHope S. Rugo, MD,Cristina Saura,Komal Jhaveri,Carlos Barrios,Sherene Loi, MD, PhD,Frederik Marme,Francois Clement Bidard,Yeon Hee Park,Peter Schmid, MD,Sarah L. Sammons,Giuseppe Curigliano

135 Elacestrant in Combination With Everolimus or Abemaciclib in Patients With ER+/HER2– Locally Advanced or Metastatic Breast Cancer (mBC): Phase 2 Results From ELEVATE, an Open-Label, Umbrella Study

ByHope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Nancy Chan,Giuliano Borges,Rinat Yerushalmi,Marina N. Sharifi,Wassim McHayleh,J. Thaddeus Beck,Neelima Vidula, MD,Erika P. Hamilton, MD,Kristine J. Rinn,Joyce O’Shaughnessy, MD,Giuseppe Curigliano,Javier Cortés, MD,Paula Muñoz Romero,Giulia Tonini,Alessandro Paoli,Monica Binaschi,Li Cheng,Jennifer Crozier,Tomer Wasserman,Virginia Kaklamani, MD, DSc

TIP136 ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-Positive, Estrogen Receptor–Positive (ER+), HER2-Negative (HER2–), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-Label Phase 3 Study

ByAditya Bardia, MD, MPH, FASCO,Virginia Kaklamani, MD, DSc,Joyce O’Shaughnessy, MD,Peter Schmid, MD,J. Thaddeus Beck,Michelino De Laurentiis,Giuseppe Curigliano,Hope S. Rugo, MD,Carlos H. Barcenas,William J. Gradishar, MD,Michail Ignatiadis,David Cameron,Giulia Tonini,Simona Scartoni,Jennifer Crozier,Tomer Wasserman,Sara M. Tolaney, MD, MPH

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Cristina Saavedra,Vicente Carañana,Isabel Blancas,Carmen Hinojo-González,Alfonso Cortes-Salgado,Elena Galve,Rui Rui Zhang,Miguel Sampayo-Cordero,Daniel Alcalá-López,Juliana Carvalho-Santos,Olga Boix,Ana Garrido,Carlos H Barrios,Giuseppe Curigliano,Rupert Bartsch,Anne Claire Hardy Bessard,Tomer Wasserman,Javier Cortés, MD

138 HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer

ByErika P. Hamilton, MD,Giuseppe Curigliano,Miguel Martin, MD, PhD,Florence Lerebours,Junji Tsurutani,Marie-France Savard,Katarzyna J. Jerzak, MD, MSc, FRCPC,Xichun Hu,Luciana Carla Martins de Aquino Pimentel,Ciara C. O’Sullivan,Eriko Tokunaga,Alicia Okines,Chiun-Sheng Huang,William Jacot,Joohyuk Sohn,Eduardo Cronemberger Silva,Volkmar Mueller,Helene Viala,Shan Yang,Giovanna Granata,Qi Shen,Libero Santarpia,Veronique Dieras
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran

Latest Updated Articles